

Table 4.27

## Cancer of the Female Breast(In Situ)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2004-2008  
Females by Race

Histology <sup>a</sup>	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native <sup>b</sup>		Hispanic <sup>c</sup>	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Adenocarcinoma <sup>d</sup>	62,981	99.7%	50,790	99.7%	5,690	99.6%	5,523	99.8%	170	100.0%	5,592	99.8%
Adenocarcinoma <i>in situ</i> , NOS (8140/2)	-	-	-	-	-	-	-	-	-	-	-	-
Ductal carcinoma <i>in situ</i> <sup>f</sup>	52,948	83.8%	42,266	83.0%	4,925	86.2%	5,023	90.8%	138	81.2%	4,771	85.1%
Cribriform carcinoma <i>in situ</i> (8201/2)	5,151	8.2%	4,069	8.0%	456	8.0%	534	9.7%	20	11.8%	481	8.6%
Ductal carcinoma <i>in situ</i> , solid type(8230/2)	3,550	5.6%	2,962	5.8%	255	4.5%	300	5.4%	-	-	297	5.3%
Ductal carcinoma <i>in situ</i> , NOS (8500/2)	21,147	33.5%	17,147	33.7%	1,925	33.7%	1,775	32.1%	58	34.1%	1,817	32.4%
Comedocarcinoma <i>in situ</i> (8501/2)	4,606	7.3%	3,736	7.3%	424	7.4%	388	7.0%	-	-	431	7.7%
Ductal carcinoma <i>in situ</i> papillary(8503/2)	1,079	1.7%	781	1.5%	154	2.7%	114	2.1%	-	-	107	1.9%
Noninfiltrating intracystic carcinoma(8504/2)	301	0.5%	208	0.4%	42	0.7%	44	0.8%	-	-	25	0.4%
Ductal carcinoma <i>in situ</i> micropapillary(8507/2)	1,607	2.5%	1,292	2.5%	179	3.1%	114	2.1%	-	-	145	2.6%
Intraductal with other types of carcinoma <i>in situ</i> (8523/2)	15,305	24.2%	11,904	23.4%	1,478	25.9%	1,734	31.3%	26	15.3%	1,446	25.8%
Lobular carcinoma <i>in situ</i> (8520/2-8521/2, 8524/2)	7,227	11.4%	6,214	12.2%	506	8.9%	301	5.4%	19	11.2%	582	10.4%
Lobular carcinoma <i>in situ</i> , NOS (8520/2)	7,202	11.4%	6,193	12.2%	503	8.8%	300	5.4%	19	11.2%	582	10.4%
Lobular CIS <sup>f</sup> with other CIS <sup>f</sup> (8524/2)	25	0.0%	21	0.0%	-	-	-	-	-	-	-	-
Intraductal and lobular <i>in situ</i> carcinoma (8522/2)	2,370	3.8%	1,976	3.9%	212	3.7%	154	2.8%	-	-	207	3.7%
Other adenocarcinomas <sup>g</sup>	422	0.7%	321	0.6%	47	0.8%	44	0.8%	-	-	32	0.6%
Other <i>in situ</i> histologies <sup>h</sup>	188	0.3%	150	0.3%	25	0.4%	-	-	-	-	-	-
Total	63,169	100.0%	50,940	100.0%	5,715	100.0%	5,532	100.0%	170	100.0%	5,604	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

<sup>d</sup> Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>e</sup> Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8230,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

<sup>f</sup> Ductal carcinoma includes histologies 8201, 8230, 8401, 8500-8507, 8523.

<sup>f</sup> CIS = Carcinoma *in situ*.

<sup>g</sup> Other adenocarcinomas include 8050, 8141-8147, 8160-8162, 8180-8200, 8202-8221, 8250-8400, 8402-8499, 8514, 8525-8551, 8560, 8570-8574, 8576, 8940-8941.

<sup>h</sup> Other histologies include 8000-8049, 8051-8139, 8148-8159, 8163-8179, 8222-8229, 8231-8249, 8508-8513, 8515-8519, 8552-8559, 8561-8569, 8575, 8577-8939, 8942-9989.

- Statistic not shown due to fewer than 16 cases during the time period.